Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — Investor Presentation (September 2021)
24 slides from Gt Biopharma's investor presentation, Sep 23, 2021
Slide 1: GT Biopharma: Target Directed NK Cell Immunotherapy
GT BIOPHARMA Target Directed NK Cell Immunotherapy NASDAQ: GTBP LET 20 September 2021, Non-Confidential
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT ‘This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, you can identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could” “estimates,” “expects,” “intends,” “may
Slide 3: GT Biopharma Recent Major Milestones
GT BIOPHARMA RECENT MAJOR MILESTONES March 2019 February 2020 February 2021 October 2019 October 2020 G8 Added to RUSSELL 2000 July 2021 June 2021 September 2021 ‘Non-Confidential
Slide 4: Company Focus — Harnessing Natural Killer Cells to Fight Cancer
Company Focus — HARNESSING NATURAL KILLER CELLS To FIGHT CANCER ‘oure: Lewy Pats of Progress 2019, Natural ile Cal: How the iene syste ist wave of etense may py a newtound olen September 2022 ted an fresno of eee 2019/atual te ced bor Restore patient’s exhausted/inhibited endogenous NK cell populati
Slide 5: What Is a TriKE Therapeutic?
WHAT IS A TRIKE® THERAPEUTIC? NK cel cos ‘Ant-CO16 @us (| corr catiner sxeewea Sea Key Therapeutic Features: * Target-directed ADCC killing. * Integrated cytokine support within the tumor micro-environment (TME). * Simultaneous NK cell ADCC activation, proliferation and persistence. * First-in-Class
Slide 6: TriKE Product Candidate Pipeline
TRIKE® PRODUCT CANDIDATE PIPELINE = Product ‘Approach Pre-Clinical © GMP Manufacturing Phase1 Phase Candidates Monetheropy Leukemia AML, MOS Phase Leukemia — AML Gre-3650 ‘Monotherapy petiee as Pre-iNo 2 Genaration Cansiil” Combination with Leukemia AML, MOS, = ces no cTe-4550—_Monotherapy & Camel C
Slide 7: TriKE Directed NK Cell Serial Killing of AML Cancer Cells
TRIKE® DIRECTED NK CELL SERIAL KILLING OF AML CANCER CELLS Integrated CD16 and IL-15 in TriKE drives: > NK cell ADCC activation for enhanced serial killing of cancer cells > NK cell proliferation > NK cell persistence * TriKE minimizes toxicities such as cytokine release syndrome (CRS) resulting fro
Slide 8: GTB-3550 TriKE Product Candidate
GTB-3550 TRIKE® PRoDUCT CANDIDATE Source Pr.) erard/eN/Scence Source First-in-Class immune oncology therapy. Target-directed NK cell ADCC killing of CD33+ hematological cancers. Incorporates IL-15 within therapeutic for enhanced NK cell proliferation and persistence. Currently being evaluated in a F
Slide 9: TriKE GTB-3550 Phase 1 Study Design
TRIKE® GTB-3550 PHASE 1 STUDY DESIGN Phase 1 ‘Safety and Dose Finding” (Sasa! =») See no et on da) Phase 1 (safety and dose fining) Phase 1 Safety Expansion "brary Endpoits Dele salty and mann orate dose, RPZ0 aed sche * Estlaon based on cotnualeassessmentmets,. Conor of2swtjeds _* Secondary Endpoin
Slide 10: GTB-3550 First in Human Clinical Trial Interim Results
GTB-3550 First IN HUMAN CLINICAL TRIAL INTERIM RESULTS jet] ve tevet auaeaita team ‘near characteris | sense characteristics | pessomse pont ae sie | ans, Sei. etre O183550 Therapy | Aer TO-350 Therapy | IPOS Pont Cre F DS LL Renae AN | Ca ee nd 5 ee For as = > et tal a a F | ERA ees Seep ied Lbreae
Slide 11: GTB-3550 TriKE Is Safe and Well Tolerated
GTB-3550 TRIKE® Is SAFE AND WELL TOLERATED Panel A: Dose Equivalent of GTB-3550 and Systemic Maximum, Panel B: Systolic Blood Pressure Therapeutic Dose of IL-15 - PER MOLE BASIS “a Dose of GTB-3550(ng/ke) | Fold Higher than MTD rhiL-15 | 3 058 Fl i E 10 108 ; 25 208 5 30 338 100 1075 150 16:13 2 Sat
Slide 12: GTB-3550 TriKE Activates Endogenous NK Cells in the Periphery, Egress into Tissues
GTB-3550 TRIKE® Activates ENDOGENOUS NK CELLS IN THE PERIPHERY, EGRESS INTO TISSUES PanelA: Increase in NK cll activation upon administration of GTB-3550. © sto = mo = Beng + 20 + 10m = 109 Panel: Increase in absolute number of NK cells during treatment. =; sae A | 3 Son \ ‘ ‘Non-Confidential 2
Slide 13: GTB-3550 TriKE Demonstrates Dose Dependent & Sustained Proliferation of Endogenous NK Cells
GTB-3550 TRIKE® DEMONSTRATES Dose DEPENDENT & SUSTAINED PROLIFERATION OF ENDOGENOUS NK CELLS Proliferating Cells Proliferating Cells Proliferating Cells Day8 Day 15 Day 22 weet stem + sate + se : sete om sme ; ne ‘ ae : 5S tants 2 sons si NK D8 NK NK ‘Non-Confidentil a
Slide 14: GTB-3550 TriKE Clinical Trial Immune Monitoring Results
GTB-3550 TRIKE® CLINICAL TRIAL IMMUNE MONITORING RESULTS No Loss of CD16 During GTB-3550 Therapy Separates cosébright and CD56dim CD56 (618-3550 Therapy Ends Day 19 Data from Patient #7 treated with 50 ug/kg/day Source Daton Fie, GT Bophorma, Ine be ‘Non-Confidentil 4
Slide 15: GTB-3550 TriKE First-in-Human Clinical Trial Interim Results
GTB-3550 TRIKE® FiRST-IN-HUMAN CLINICAL TRIAL INTERIM RESULTS * GTB-3550 TriKE induces reproducible NK cell proliferation in all patients at all dose levels evaluated with no clinically significant toxicity. No CRS resulting from hyperactivation of patient’s T-cell population at doses 5 — 100 yjg/kg
Slide 16: Camelid Antibodies — Second Generation TriKE
CAMELID ANTIBODIES — SECOND GENERATION TRIKE® + Camelid antibodies are antibodies from the Camelidae family of mammals that include llamas, camels, and alpacas. + Camelid antibody is made up of only 2 heavy chains. This is known as heavy chain IgG (hclgG). While these antibodies do not contain the C
Slide 17: Second Generation TriKE (Camelid) Improves NK Function
SECOND GENERATION TRIKE® (CAMELID) IMPROVES NK FUNCTION CD 33+ HL60 Targets 8 30 mee sch16m 15-33 (678-3550) me scrv16-m 15-33 (678-3550) g ae cam 16-1533 (678-3650) a cam 16-15-33 (678-3650) FS & 3 %IFNg+ NK Cells %CD107a+ NK Cells 0.01 O41 1 10 100 0.01 O41 1 10 100 Concentration (nM) Concentratio
Slide 18: Second Generation TriKE (Camelid) Superior In-Vivo
SECOND GENERATION TRIKE® (CAMELID) SUPERIOR IN-VIVO 68 i sceviemss3,eee ) z —___—_—_—_—_—_C_ 10 14 Gye Da EES rt T T @ 0 2 7 44 21 s” mor Sw ny 10° yecee s " S Se & Source: ees Met Cone nl 2020S 1230-1169 ‘Non-Confidential
Slide 19: Pipeline TriKE B7H3: Pan Cancer Solid Tumor Targeting
PIPELINE TRIKE® B7H3: PAN CANCER SOLID TUMOR TARGETING Matas Day 21 After MA-148 Tumor Implant 2% = = 8,.| Het Hel tuner [eliotn Ba Fe $4 5 NK+ Ba 115 ° z > 8 & § & Ff Fp oe fa NK+ OMe NS TriKE® B7H3 e s Dosing: 5x/week (MTWThF) Schedule: 3 weeks Significant killing of MA148 Ovarian Cancer by TriKE®
Slide 20: TriKE Makes NK Cell Therapies More Effective
TRIKE® Makes NK CELL THERAPIES More EFFECTIVE Clear Competitive Advantage in Solid Tumor Cancers PC-3 Prostrate Cancer Cells 3 Cells IPSC NK Cells IPSC NK Cells IPSC NK Cells qilas +B7H3 TrikE™ Pcs. iad cultures Targets + INK +ILIS Targets + INK + B7HSTHKE tmmunether Cancer 2020} vol. 8(supp3}, Abst
Slide 21: Multi-Layered Patent Strategy
Mutti-LAYERED PATENT STRATEGY TrikE® Method of Use Patent Claims ‘+ Methods of use claims highlighting coverage for oncology and infectious disease therapeutic applications. TriKE® Composition of Matter Patent Claims ‘+ Composition of matter claims covering DNA and amino acid sequences for all TriKE
Slide 22: Competition
COMPETITION TriKE® Competitive Advantages > The anti-CD16 component of the TrikE binds FcRyIII at high affinity compared to ADCC mediated strategies that bind at low affinity. > CD16 +/- other receptor engagement does not result in proliferation of T-cells contributing to CRS. > IL-15 provides NK ce
Slide 23: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM PROVEN RECORD IN BIOTECH, PHARMA, PRODUCT DEVELOPMENT, FINANCING = —_— = Michael Handeiman, CPA cua Mae MO TOVANCE caevete CD Gversiem intettikine TOVANCE OX: pum: Dae os © me ay = ———) Govin Choy, PharmD, MBA hel Case Beveopmet ees Stacy Her, MPH, MBA fepotomes JA SEE [e
Slide 24: GT Biopharma
GT BIOPHARMA Target Directed NK Cell Immunotherapy NASDAQ: GTBP LET 20 September 2021, Non-Confidential 2
GT Biopharma — Investor Presentation (September 2021) on 6ix